TGFB2 and cancer: Our study builds upon this knowledge by using TGF-β-TRAP/AVID-200, a ligand trap that effectively depletes only TGF-β1/3, which are most associated with cancer progression, and not TGF-β2, which is critical in hematopoiesis and cardiac function (6).